Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) was up 1.7% on Thursday . The company traded as high as $3.1799 and last traded at $3.08. Approximately 20,139 shares changed hands during trading, a decline of 98% from the average daily volume of 1,049,645 shares. The stock had previously closed at $3.03.
Virios Therapeutics Stock Performance
The company has a 50 day moving average price of $4.43 and a 200 day moving average price of $5.09. The company has a market capitalization of $59.31 million, a PE ratio of -11.41 and a beta of 1.58.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.
The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.
See Also
- Five stocks we like better than Virios Therapeutics
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- When to buy gold (mathematically)
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- GOLD ALERT
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
